JPH0676333B2 - ヘモグロビン―ポリオキシアルキレン結合体 - Google Patents

ヘモグロビン―ポリオキシアルキレン結合体

Info

Publication number
JPH0676333B2
JPH0676333B2 JP61142302A JP14230286A JPH0676333B2 JP H0676333 B2 JPH0676333 B2 JP H0676333B2 JP 61142302 A JP61142302 A JP 61142302A JP 14230286 A JP14230286 A JP 14230286A JP H0676333 B2 JPH0676333 B2 JP H0676333B2
Authority
JP
Japan
Prior art keywords
hemoglobin
polyoxyalkylene
polyoxyethylene
solution
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP61142302A
Other languages
English (en)
Other versions
JPS6289630A (ja
Inventor
敬治 岩崎
健俊 岡見
晃徳 権正
昭 矢吹
雄二 岩下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Fujirebio Inc
Original Assignee
Ajinomoto Co Inc
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc, Fujirebio Inc filed Critical Ajinomoto Co Inc
Publication of JPS6289630A publication Critical patent/JPS6289630A/ja
Publication of JPH0676333B2 publication Critical patent/JPH0676333B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

【発明の詳細な説明】 産業上の利用分野 本発明は、代用血液中に必要な酸素運搬物質として使用
する新規なヘモグロビン−ポリオキシアルキレン結合体
に関する。
従来の技術 代用血液に使用する酸素運搬物質としてヘモグロビン−
ポリオキシアルキレン結合体が血流内寿命を大幅に延ば
すことができる点で優れていることは既に明らかにされ
ている（特開昭56-12308号,57-206622号明細書参
照。）。
発明が解決しようとする問題点 ヘモグロビンが生体成分であるところから、ポリオキシ
アルキレンを結合させることによりヘモグロビンが変性
したり酸素親和性を減少させたりする問題があった。さ
らに、得られたヘモグロビン−ポリオキシアルキレン結
合体の保存性特にポリオキシアルキレン−ヘモグロビン
間の結合の安定性にも問題があった。
問題点を解決するための手段 本発明者はこのような問題点を解決するべく種種検討の
結果、末端にエーテル結合を介してカルボキシル基を有
するポリオキシアルキレンを用いてこれにヘモグロビン
をアミド結合させて得られた結合体は前記問題点を解決
したものであることを見出して本発明を完成するに至っ
た。
すなわち、本発明は、ポリオキシアルキレン末端とヘモ
グロビンのアミノ基との結合部分が下記の構造式よりな
るヘモグロビン−ポリオキシアルキレン結合体に関する
ものである。
‐CH2‐O-(CH2)n‐CONH-Hb （式中、Hbはヘモグロビンを表わし、ｎ＝１〜７であ
る。） 本発明で用いられるポリオキシアルキレンは、例えばポ
リオキシエチレン（エチレンオキサイドの重合体でポリ
エチレングリコールともいう。）、ポリオキシプロピレ
ンあるいはエチレンオキサイドとプロピレンオキサイド
との共重合体等水溶性の高い重合物であり、その分子量
は300〜20,000、製造される結合体の粘度等の観点から
好ましくは750〜10,000、特に好ましくは1000〜6000、
の範囲内にあるものである。
ポリオキシアルキレンの末端とカルボキシル基部分との
間の結合にはエステル結合、アミド結合、エーテル結合
等が考えられる。これらの結合のうちで特にエーテル結
合が有効であることを見出してなされたのが本発明であ
る。従って、本発明のヘモグロビン−ポリオキシアルキ
レン結合体の合成に使用されるポリオキシアルキレンは
ヘモグロビンを結合させる末端が‐O-(CH2)n‐COOHに変
換されているものである。ｎは１〜10程度であり、１〜
７程度、特に１〜３程度のものが選択されることが多
い。
ポリオキシアルキレンの末端をこのような形に変換する
方法としては、白金、パラジウムの炭素担持触媒を用い
て末端炭素を酸化する方法、活性化二酸化マンガンで末
端のオキシメチル基を酸化してアルデヒドに変え、過酸
化水素でさらに酸化してカルボン酸にする方法、塩基の
存在下でポリオキシアルキレンにハロゲン化脂肪酸を反
応させる方法、ジアゾ基を有する脂肪酸とポリオキシア
ルキレンを反応させる方法などを利用すればよい。
このようにカルボキシル基を付与されたポリオキシアル
キレンとヘモグロビンの反応に際して、例えばＮ−ヒド
ロキシコハク酸イミド、Ｎ−ヒドロキシフタル酸イミ
ド、ｐ−ニトロフェノール、ペンタクロロフェノール等
通常のペプチド合成におけるカルボン酸活性化剤により
活性エステルとし、これとヘモグロビンと反応させてア
ミド交換することもできるし、塩化チオニル等ハロゲン
化剤を作用させてポリオキシアルキレンの酸ハロゲン化
物とし、これとヘモグロビンとを反応させることもでき
る。
本発明に使用するヘモグロビンは、ヒト、ウシ、ブタ、
ヒツジ、ウマ、イヌ、サル、ウサギ、ニワトリ等ヘモグ
ロビンを有する動物由来のものであればよい。本明細書
でいうヘモグロビンとは、いわゆる異常ヘモグロビン
（K.Imai,Alloaterle Effects in Haemoglobin,Cambrid
ge University Press,1980参照）あるいはピリドキサー
ル−リン酸例えば、ピリドキサール−５′−リン酸、２
−ノル−２−ホルミルピリドキサール−５′−リン酸、
ピリドキサール−硫酸、例えばピリドキサール−５′−
硫酸、グリセリンリン酸類、例えばグリセリン−2,3−
ジリン酸、糖リン酸、例えばグルコース−６−リン酸、
アデノシン−５′−リン酸等のヘモグロビン誘導体であ
ってもよい。
ヘモグロビンの反応時の濃度は、0.5〜20％（重量）程
度、好ましくは0.5〜10％（重量）程度である。しかし
ながら、アミノ酸等が共存せずヘモグロビン濃度が４％
を越えた場合には、架橋反応が進んで高分子化しゲル化
しやすくなるので反応の管理に注意を要する。一方、ヘ
モグロビンが低濃度になると反応容器が大型化するとと
もに反応後に濃縮が必要になるので好ましくない。
ポリオキシアルキレンの使用量は、ヘモグロビン１モル
に対して１〜50モル程度、好ましくは２〜10モル程度で
ある。
ポリオキシアルキレンとヘモグロビンとの結合反応にお
いてアミノ酸又はアミンを共存させることにより、生成
するヘモグロビン−ポリオキシアルキレン結合体の分子
量をコントロールすることができる。これはポリオキシ
アルキレンの活性化されたカルボキシル基の一部にアミ
ノ酸又はアミンを結合させてヘモグロビンへの結合を阻
止することによる。この方法により、ヘモグロビンを希
薄溶液としなくとも好ましい結合体を得ることができ
る。
反応時に存在せしめるアミノ酸は、例えば蛋白質の構成
アミノ酸を使用すればよく、リジン、アルギニン、ヒス
チジン等の塩基性アミノ酸、グリシン、フェニルアラニ
ン等の中性アミノ酸、グルタミン酸、アスパラギン酸等
の酸性アミノ酸が例示される。一方、アミンはアンモニ
ア、脂肪族アミン、芳香族アミンのいずれでもよいが、
本物質が血流内に投与される関係から安全性の高いもの
が好ましい。アミノ酸及びアミンは１種であってもよ
く、２種以上であってもよい。アミノ酸又はアミンのア
ミノ基が第３級である場合には活性エステルの分解を触
媒することによりヘモグロビンと結合していないポリオ
キシアルキレンの末端は‐O-(CH2)n‐COOHの形をとる。
一方、第１級又は第２級の場合には末端が‐O-(CH2)n‐
CONHRとなり、Ｒの種類によってヘモグロビン表面の電
荷や疎水性を変えることができる。これによって本発明
の結合体を代用血液に用いた場合に生体内の血液との混
合によって接する赤血球、白血球、血漿タンパク等との
相互作用を変えて免疫的認識等を好ましい方向に変える
ことができる。アミノ酸の使用量はヘモグロビン１モル
に対し１〜100モル程度、好ましくは５〜20モル程度で
ある。
ヘモグロビンとポリオキシアルキレンとを結合させる反
応時に、酸素不存在か酸素低濃度とするのが好ましい、
酸素分圧として０〜30mmHg程度を選択すればよい。上記
酸素濃度以外の反応条件は、ヘモグロビンの変性を伴わ
ない条件であればいずれであってもよい。
酸素の濃度を低下させるには、窒素、アルゴン、ヘリウ
ム等の不活性ガスで反応容器中の空気を置換する方法、
容器中の酸素を還元剤（NaBH4、Na2S2O3等）によって還
元し除去する方法、ポンプ等で脱ガスしアルゴン等の不
活性ガスで置換する方法等、公知の方法を採用すること
ができる。
このようにして得られたヘモグロビン−ポリアルキレン
結合体は通常は凍結乾燥して製剤化する。
作用 本発明のヘモグロビン−ポリオキシアルキレン結合体
は、エーテル結合を介してカルボン酸が結合した形のポ
リオキシアルキレンを用いることによって、ヘモグロビ
ンの酸素親和力を低下させないばかりでなく、安定性の
高い結合体になっている。
例えばポリオキシエチレン4000の末端が-OCO(CH2)2COO
H、-NHCO(CH2)2COOH、-O-CH2COOHの３種のポリオキシエ
チレンを調製し、これらのポリオキシエチレンと結合さ
せた３種のポリオキシエチレン−ヘモグロビン結合体の
加水分解反応に対する抵抗性を比較したところ次のよう
な結果が得られた。すなわち、上記エステル型（Ｉ）、
アミド型（II）、エーテル型（III）の各々５％水溶液
（pH7.0 0.1規定リン酸緩衝液）を35℃で１週間インキ
ュベートし、分解によって生じたポリオキシエチレンを
定量したところ、III＞II＞Ｉの順となった。そこで、
最も安定性が秀れているのがエーテル型である事が明ら
かとなった。
以下実施例で本発明の詳細を説明する。
なお、これらの実施例において、生成物の分子量はプレ
パックドゲル（Prepacked）型カラムSW3000G（東洋ソー
ダ（株）、日本）を用い高速液体クロマトグラフィーよ
り測定した。
なお用いた展開溶媒は0.1Mリン酸緩衝液（pH＝6.8）を
使用し、分子量はファルマシア社製（Pharmacia Fine C
hem.,Sweden）の分子量決定のための標準タンパク質キ
ットを用いて検量線を求め、溶出量より推定した。
またヘモグロビン１分子当りの結合ポリアルキレン分子
数は、限外過により完全に塩類と未反応ポリオキシア
ルキレンを除去して、凍結乾燥（脱水）した後、重量測
定し、その後吸光度より算出して当該サンプル中のヘモ
グロビン量を差引く事によって求めた。
またえられた安定化ヘモグロビンの酸素解離曲線の測定
はpH7.4の0.1Mリン酸緩衝液を用い、今井らの方法（K.I
mai.H.Morimoto,M.Kotani,H.Waka,M.Kuroda,Biochim.Bi
ophys.Acta.,200,189〜196(1970)）によっておこなっ
た。
実施例１ 分子量1000ダルトンのポリオキシエチレン（Aldrich Ch
emical Co.,USA）30g（30mモル）と３−クロロプロピオ
ン酸エチル16.4g（120mモル）を乾燥したジメチルホル
ムアミド700mlに溶解し、これに20gの酸化銀を加え70°
で24時間反応したのち沈殿物を過により除去した。
えられた液は3lの冷却したエチルエーテル中にそそ
ぎ、ポリオキシエチレン誘導体を沈殿させた。
沈殿物はエチルエーテルで洗浄後乾燥し、水300mlに再
び溶かし、１規定水酸化ナトリウム水溶液をpH11以上に
なるまで加え、60℃で一夜攪拌してエステルの加水分解
をおこなった。
１規定塩酸で反応液を中和してpH5とし、濃縮、乾固し
た。
えられた生成物は塩化メチレン−エーテルの1:1混合溶
液200mlに溶かし不溶物を別したのち濃縮し、白色粉
末を沈殿によってえた。
えられた固型物を水100mlに溶解したのち強塩基性イオ
ン交換樹脂Bio-Rad AGIX2（Bio-Rad Laboratories,US
A）にかけ、吸着物を0.05規定塩酸で溶離した。
生成物は18gの白色結晶であった。
この生成物（ポリオキシエチレンのジカルボン酸誘導
体）10gとＮ−ヒドロキシコハク酸イミド6.5g（56.5ミ
リモル）をジメチルホルムアミド200mlに溶かし、ジシ
クロヘキシルカルボジイミドで脱水縮合してポリオキシ
エチレン1000の活性エステル9.8gをえた。
一方ウシの新鮮赤血球100mlを0.9％食塩水に浮遊させ遠
心分離機を用いて４℃で４回洗浄した。
ウシ洗浄赤血球60mlを同容の注射薬用蒸留水を用いて溶
血し孔径0.22μのフィルター（Millipore Co.,USA）を
用いて膜成分を除いた。さらに残存する膜成分は遠心分
離機で6000回転１時間遠心分離して除いた。
えられたウシヘモグロビン溶液10gを200mlのホウ酸0.1
モル緩衝液pH7.0に溶解し、えられた溶液（0.15ミリモ
ル）に活性ポリオキシエチレン4.7g（3.5ミリモル）と
リジン212mg（1.45ミリモル）を加え、アルゴンで酸素
分圧1mmHgまで引下げたあと４℃で２時間反応させた。
えられた反応液は分画分子量10,000ダルトンの限外過
膜YM-10（Amicon Co,UAS）で未反応ポリオキシエチレン
が100ppm以下になるまでくり返し精製した。
生成した反応液のゲル過クロマトグラフィーにおける
ピークの面積比から原料ヘモグロビンは、ほとんど残存
せず、第１図に例示するような単量体型（Ａ），二重体
型（Ｂ），三重体型（Ｃ）がほぼ5:3:1で混合している
事が判明した。尚、図中丸４つでヘモグロビン分子を表
わし、カギ形はポリオキシエチレンを表わしている。
またヘモグロビン分子１個あたりについているポリオキ
シエチレンの結合分子数は6.3個であった。
またP50即ち酸素解離曲線において50％の酸素が化学修
飾ヘモグロビンに配位する時の酸素分圧は25℃で13.7mm
Hgであった。また、結合ポリオキシエチレンの末端にリ
ジン基が存在する事が加水分解物のアミノ酸分析より明
らかにされた。
実施例２ 特開昭53-141219（川研ファインケミカル（株））に述
べられている方法で調製した白金パラジウム炭素触媒20
gと市販のポリオキシエチレン（日本油脂（株），日
本）（Macrogoal 4000）200gを含む水溶液500mlを1.5l
オートクレーブ中に入れ、加圧空気を導入して圧力を10
kg/cm2とし、90℃で10時間反応させた。
反応生成物は過により触媒を除去したのち、活性炭で
処理し、さらに水から再結晶し180gの両末端にカルボキ
シル基を有するポリオキシエチレンの酸誘導体（α−カ
ルボキシメチル−ω−カルボメトキシポリ（エチレンオ
キシド））をえた。
この分子量約4000のポリオキシエチレンの酸誘導体20g
（５ミリモル）、Ｎ−ヒドロキシコハク酸イミド4g及び
ジシクロヘキシルカルボジイミド（DCC）7gをジメチル
ホルムアミド100mlに溶かし一夜攪拌した。生成した結
晶のジシクロヘキシル尿素を分離したのち、エチルエー
テル400mlを加えてポリオキシエチレンの活性化エステ
ル17gを沈殿させ、別後更にエーテルで洗浄した。一
方期限切れ輸血用血液より得られたヒト赤血球50mlを0.
9％の食塩水50mlで遠心分離機を用いて４℃で４回洗浄
した。
上記の操作でえられた洗浄赤血球40mlを注射薬用蒸留水
40mlに加えて溶血したあと、20mlのトルエンにて膜成分
を抽出した。えられたヘモグロビン液は8000回転で１時
間遠心分離を行う事によって更に膜成分とヘモグロビン
を分離した。
ヘモグロビン溶液は0.1Mリン酸緩衝液に溶解し濃度を6g
/dl（0.088mM）,pH7.0とした。ついでこのヘモグロビン
溶液1.00mlに酸素分圧が2mmHg以下になるまで激しくア
ルゴンをふき込む事により脱酸素したのち、ベネシェら
の方法（R.Benesch,R.Benesch,S.Kwong,A.Acharya,J.Ma
nning,J.Biol.Chem 257(3)1320-24(1982)）によりピリ
ドキサール−５′−リン酸を付加し、ピリドキサール化
ヘモグロビン（6g/dl）をえた。
これにグリシン160mlを加えた後、上記の方法でえたポ
リオキシエチレンの活性化エステル7.2gを加え、30分４
℃で反応した。ついで、１規定水酸化ナトリウム水溶液
を加えpH7.8にしたのち更に30分反応させた。
反応液は分子量分画３万の限外過膜YM30（Amicon社,U
SA）により限外過をくり返し、未反応のポリオキシエ
チレンの濃度が100ppm以下にした。
実施例１で述べたゲルタイプの充填カラムを用いた高速
液体クロマトグラフィーから生成物の分子量は約9.8万
ダルトンと推定された。なおポリオキシエチレンのヘモ
グロビンと結合していない方の末端にはグリシンが結合
している。
実施例３ 市販のプルロニック（Pluronic）P123,分子量4000ダル
トン（エチレンオキサイドとプロピレンオキサイドのブ
ロック共重体（BASF Wayandotte Co,USA））20g（５ミ
リモル）をよく脱水したジオキサン中1gの金属ナトリウ
ムと反応させ、プルロニックの２ナトリウム塩をえた。
沈殿物を過後、この過液に、モノクロロ酢酸エチル
エステル2mlを滴下し50℃で24時間反応させた。
えられた反応液は実施例１で述べた方法により、エステ
ルを加水分解後、沈殿をくり返す事により精製した。
更にプルロニックの両末端にカルボキシル基を有するこ
のポリアルキレングリコール誘導体は実施例２で述べた
方法を用いてＮ−ヒドロキシコハク酸イミドと反応させ
活性エステルとした。
一方実施例２の方法によってえられたヒトヘモグロビン
の６％溶液（0.09ミリモル）100ml（pH7.4のホウ酸緩衝
溶液）に窒素ガスを吸込む事により酸素分圧を5mmHgに
下げたのち、上記によってえられたプルロニックの活性
エステル7g（1.7ミリモル）とＬ−アラニン250mg（2.8
ミリモル）を加え４℃で１時間反応させた。
次いでpH7.8に上げ更に30分攪拌し実施例１の方法で精
製した。
高速液体クロマトグラフィーによって推定した分子量は
95,000ダルトン，ヘモグロビン分子１個あたりのプルロ
ニック結合数は4.8であった。また酸素解離曲線より推
定された50％酸素解離圧（P50）は25℃で6.1mmHgであっ
た。
実施例４ ポリオキシエチレンメチルエーテル分子量1900（Aldric
h Chemical Co.USA）15g（7.9ミリモル）を乾燥したジ
クロロメタンに溶解し、30gの活性化二酸化マンガンを
加え、室温で一夜攪拌し反応させた。
過により触媒を分離したのち、アルデヒド型に酸化さ
れたポリオキシエチレン誘導体は、溶媒を減圧下で留去
したのち３％の過酸化水素水500mlに溶解し24時間反応
させた。
反応液はBio-Rad AGI×２を充填したカラムを通し中性
物を除去したのち0.02M HClで末端にカルボキシル基を
有するポリオキシエチレン誘導体を分離した。
この酸誘導体5g（2.6ミリモル）を乾燥したジメチルホ
ルムアミド100mlに溶解し0.8g（7.0ミリモル）のＮ−ヒ
ドロキシコハク酸イミドと1.5g（7.2ミリモル）のジシ
クロヘキシルカルボジイミドを加えて一夜室温で反応さ
せた。
不溶物を別後、乾燥エーテルを沈殿が生成するまで加
え活性化エステルをえた。
一方、実施例２により調製したヒトヘモグロビンの６％
溶液300mlを20倍過剰のグリオキザール酸とHEPES緩衝液
中でディドナートらの方法（A.DiDonato,W.Fartl,A.Ach
arya,J.Manning,J.Biol,Chem.258(19)11890〜895(198
3)）で反応させひきつづきNaBH3CNで還元した。
えられたカルボキシメチル化したヘモグロビンはセファ
デックスG-100で低分子物質を除き、さらに0.1Mのリン
酸緩衝液で5.2g/100mlの溶液とし、4.8gの上記の手法に
よってえられたポリオキシエチレンモノメチルエーテル
の活性化エステルと５℃２時間反応させた。
生成物は実施例１の限外過の手法で精製した。前記の
高速液体クロマトグラフィーで測定した分子量は8.2万
ダルトン、P50＝12mmHg（25℃,pH7.4）であった。
実施例５ ポリオキシエチレン平均分子量8,000ダルトン（Aldrich
Chemical Co.USA）20g（2.5ミリモル）を用い実施例２
で示した方法で該当するポリオキシエチレンの両末端に
‐O-CH2‐CO2Hを持つカルボン酸をえた。
このカルボン酸をBio-Rad AGI×２の樹脂で精製したあ
と実施例２の方法でＮ−ヒドロキシコハク酸イミドと反
応させ活性エステルとした。一方実施例１で示した方法
によってえられたウシヘモグロビン7gを用い、これをpH
7.4のリン酸緩衝液に溶解して0.1M溶液（100ml）を作
り、前記ベネシェらの方法でピリドキサール−５′−リ
ン酸と反応させ、ひきつづき水素化ホウ素ナトリウム
（NaBH4）で還元した。
この溶液を高純度窒素で脱酸素後、Ｎ−ジメチルグリシ
ン1500mgと4.8gの活性化ポリオキシエチレンエステルを
加え４℃の低温で１時間反応させた。
反応液は実施例１で述べた方法を用いて低分子量の物質
を除き精製した。
シアンメトヘモグロビン法でヘモグロビン濃度を測定し
た。収率はウシヘモグロビンから計算して63％であっ
た。
また平均分子量12万ダルトン,6％のヘモグロビン濃度の
溶液の粘度は2.8cpsであった。
今井の方法（前述）で測定した酸素解離曲線からP50＝1
9mmHg（25℃,pH＝7.4）がえられた。
実施例６ 10.9％のヒトヘモグロビン溶液20ml（0.034ミリモル）
を0.122Mのトリス緩衝液（pH6.8）90mlに溶解した液に
容量200mlの三つ口フラスコに入れ、アルゴンガスを１
時間通気した。
引き続き、アルゴンガスを通気しつつ、ピリドキサール
５リン酸エステル−水和物33mg（0.125ミリモル）を加
え、さらに１時間アルゴンガスを通気した後、水素化ホ
ウ素ナトリウム（NaBH4）25mg（0.66ミリモル）を加え
てさらに１時間アルゴンガスを通気し、溶液１を得た。
一方、ポリオキシエチレン（Aldrich Chemical Co.US
A、平均分子量3400）をジョーンズ試薬で酸化し、両端
にカルボキシメチル基を有するポリオキシエチレンを調
整し、これとＮ−ヒドロキシコハク酸イミドとを反応さ
せて活性化ポリオキシエチレン（α−カルボキシメチル
−ω−カルボメトキシポリ（エチレンオキシド）のＮ−
ヒドロキシコハク酸イミドエステル）を得た。
溶液１に活性化ポリオキシエチレン3.29g（0.91ミリモ
ル）を加えて４℃で一夜攪拌した後に分子量阻止30,000
の限外過膜により限外過を繰り返し、未反応の活性
エステルまたはその分解物を除去することにより、4.5
％の修飾ヘモグロビン溶液41mlを得た。これを標準修飾
ヘモグロビン溶液とする。なお、この修飾ヘモグロビン
は分子量約86,000ダルトン、置換度6.2であってP50（リ
ン酸緩衝液、pH7.40、25℃）は11.0mmHgであった。
発明の効果 本発明のヘモグロビン−ポリオキシアルキレン結合体は
ヘモグロビンを変性させず酸素親和力を損なわない。ま
た、安定性が高く、製剤化工程及び保存時においてその
活性を長く維持する。
【図面の簡単な説明】
第１図は本発明のヘモグロビン−ポリオキシアルキレン
結合物の単量体、二重体及び三重体を模式的に示した図
である。
───────────────────────────────────────────────────── フロントページの続き (72)発明者 矢吹 昭 神奈川県川崎市川崎区鈴木町１−１ 味の 素株式会社中央研究所内 (72)発明者 岩下 雄二 神奈川県川崎市川崎区鈴木町１−１ 味の 素株式会社中央研究所内 審査官 松浦 新司 (56)参考文献 特開 昭59−104323（ＪＰ，Ａ) 特開 昭59−89629（ＪＰ，Ａ) 特開 昭57−206622（ＪＰ，Ａ) 特開 昭61−53223（ＪＰ，Ａ)

Claims (6)

    【特許請求の範囲】
  1. 【請求項１】ポリオキシアルキレン末端とヘモグロビン
    のアミノ基との結合部分が下記の構造式よりなるヘモグ
    ロビン−ポリオキシアルキレン結合体。 ‐CH2‐O-(CH2)n‐CONH-Hb （式中、Hbはヘモグロビンを表わし、ｎ＝１〜７であ
    る。）
  2. 【請求項２】ポリオキシアルキレンのヘモグロビンが結
    合されていない末端の少なくとも50％にアミノ酸がアミ
    ド結合されている請求項１記載のヘモグロビン−ポリオ
    キシアルキレン結合体。
  3. 【請求項３】アミノ酸が蛋白質の構成アミノ酸のいずれ
    かである請求項２記載のヘモグロビン−ポリオキシアル
    キレン結合体。
  4. 【請求項４】ポリオキシアルキレンがポリオキシエチレ
    ン、ポリオキシプロピレン又はエチレンオキサイドとプ
    ロピレンオキサイドの共重合体のいずれかである請求項
    １記載のヘモグロビン−ポリオキシアルキレン結合体。
  5. 【請求項５】ポリオキシアルキレンの分子量が1000〜60
    00の範囲内にある請求項４記載のヘモグロビン−ポリオ
    キシアルキレン結合体。
  6. 【請求項６】代用血液用酸素運搬剤の有効成分として存
    する請求項１記載のヘモグロビン−ポリオキシアルキレ
    ン結合体。
JP61142302A 1985-06-19 1986-06-18 ヘモグロビン―ポリオキシアルキレン結合体 Expired - Lifetime JPH0676333B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13205685 1985-06-19
JP60-132056 1985-06-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP6057162A Division JP2501543B2 (ja) 1994-03-28 1994-03-28 ヘモグロビン−ポリオキシアルキレン結合体凍結乾燥製剤

Publications (2)

Publication Number Publication Date
JPS6289630A JPS6289630A (ja) 1987-04-24
JPH0676333B2 true JPH0676333B2 (ja) 1994-09-28

Family

ID=15072486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61142302A Expired - Lifetime JPH0676333B2 (ja) 1985-06-19 1986-06-18 ヘモグロビン―ポリオキシアルキレン結合体

Country Status (4)

Country Link
US (1) US4670417A (ja)
EP (1) EP0206448B1 (ja)
JP (1) JPH0676333B2 (ja)
DE (1) DE3675588D1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667292B1 (en) 1999-02-08 2003-12-23 Hokkaido University Nitric monoxide metabolite-polyoxyalkylene-hemoglobin complex

Families Citing this family (999)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753616A (en) * 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5955581A (en) * 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5439882A (en) * 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
AU658821B2 (en) * 1990-03-14 1995-05-04 University Of Toronto Innovations Foundation, The Acyl phosphate esters and modification of proteins therewith
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5216605A (en) * 1990-06-28 1993-06-01 Eaton-Kenway, Inc. Update marker system for navigation of an automatic guided vehicle
US5248766A (en) * 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
WO1992008478A1 (en) * 1990-11-20 1992-05-29 Enzon, Inc. Method of enhancing long-term storage stability of hemoglobin products
US5250665A (en) * 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5334705A (en) * 1991-08-15 1994-08-02 Duke University Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
EP0611306B1 (en) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5264555A (en) * 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
ATE190633T1 (de) * 1993-04-27 2000-04-15 Cytotherapeutics Inc Membran aus einem acrylnitrilpolymer
US5516703A (en) * 1993-08-20 1996-05-14 The University Of Utah Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5578564A (en) * 1993-07-23 1996-11-26 Somatogen, Inc. Nickel-free hemoglobin and methods for producing such hemoglobin
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5665869A (en) * 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
CN1229385C (zh) * 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US5691452A (en) * 1995-03-23 1997-11-25 Biopure Corporation Method for preserving a hemoglobin blood substitute
US6271351B1 (en) 1995-03-23 2001-08-07 Biopure Corporation Method for preserving a hemoglobin blood substitute
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
TR199701526T1 (xx) 1995-06-07 1998-03-21 Glaxo Group Limited Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler.
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5868868A (en) * 1995-06-19 1999-02-09 Alcon Laboratories, Inc. Peg-modified proteases and methods of use in contact lens cleaning
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ATE330644T1 (de) * 1995-12-18 2006-07-15 Angiotech Biomaterials Corp Vernetzten polymerisatmassen und verfahren für ihre verwendung
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
CA2249206A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
AU4648697A (en) * 1996-09-23 1998-04-14 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
JP3092530B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
DE69737457T2 (de) 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
AU735799C (en) * 1997-02-28 2005-04-28 Regents Of The University Of California, The Methods and compositions for optimisation of oxygen transport by cell-free systems
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
WO2000039297A2 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
EP0981618B2 (en) 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
CA2293724C (en) 1997-06-05 2010-02-02 Xiaodong Wang Apaf-1, the ced-4 human homolog, an activator of caspase-3
EP2083079A1 (en) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ES2331900T3 (es) * 1997-08-26 2010-01-19 Genentech, Inc. Receptor rtd.
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
CA2382506A1 (en) 1997-09-17 1999-03-25 Genentech, Inc. Novel polypeptides and nucleic acids encoding pro293 which are useful for treating disorders of the pancreas
WO1999014330A1 (en) 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
US20050158273A1 (en) * 1997-09-25 2005-07-21 Harris J. M. Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution
EP1021542B1 (en) 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
ATE409225T1 (de) 1997-10-29 2008-10-15 Genentech Inc Durch wnt-1 induzierbare gene
EP2014770A3 (en) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ES2288649T3 (es) 1997-11-21 2008-01-16 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
JP3786832B2 (ja) * 1998-01-07 2006-06-14 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 分解性のヘテロ二官能性ポリ（エチレングリコール）アクリレート及びそれから誘導されるゲル及び複合体
US6740739B1 (en) 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
DE69939374D1 (de) 1998-03-17 2008-10-02 Genentech Inc Zu vegf und bmp1 homologe polypeptide
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP2058334B1 (en) * 1998-06-12 2012-10-31 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
PT1783222E (pt) 1998-10-23 2012-07-26 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1792989A1 (en) 1999-04-12 2007-06-06 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
EP2365081A3 (en) 1999-04-12 2012-07-18 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
EP1978029A3 (en) 1999-06-15 2008-10-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
US6231825B1 (en) * 1999-07-29 2001-05-15 Rohm And Haas Company Production of sodium borohydride from sodium borohydride dihydrate in a fluidized bed dryer
WO2001012811A1 (en) 1999-08-12 2001-02-22 Urogenesys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
DK1220913T3 (da) 1999-10-05 2009-03-16 Agensys Inc G-protein-koblet-receptor opreguleret i prostatacancer og anvendelser deraf
US6180598B1 (en) * 1999-10-07 2001-01-30 Deanna J. Nelson Covalently modified hemoglobin having low temperature-dependent oxygen-binding function
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
EP2292657A1 (en) 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
JP2003514524A (ja) 1999-11-18 2003-04-22 コルバス・インターナショナル・インコーポレイテッド エントセリアーゼをコードしている核酸、エンドセリアーゼおよびその使用
US6703480B1 (en) * 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
CA2397207C (en) 2000-01-13 2013-12-03 Genentech, Inc. Novel stra6 polypeptides
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
CA2396793A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US6740520B2 (en) * 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
US20040086970A1 (en) * 2000-03-22 2004-05-06 Genentech, Inc. Novel cytokine receptors and nucleic acids encoding the same
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE10031744A1 (de) 2000-06-29 2002-01-17 Sanguibio Tech Ag Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung
DE10031740A1 (de) 2000-06-29 2002-02-14 Sanguibio Tech Ag Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030077590A1 (en) * 2000-09-22 2003-04-24 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20030044803A1 (en) * 2000-09-22 2003-03-06 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US20020115058A1 (en) * 2000-09-22 2002-08-22 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US6576452B1 (en) 2000-10-04 2003-06-10 Genencor International, Inc. 2,5-diketo-L-gluconic acid reductases and methods of use
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
US7820447B2 (en) * 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030099963A1 (en) * 2000-12-22 2003-05-29 Morris David W. Novel compositions and methods in cancer associated with altered expression of TBX21
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030232334A1 (en) 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20030165878A1 (en) * 2000-12-22 2003-09-04 Morris David W. Novel compositions and methods in cancer associated with altered expression of MCM3AP
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6518010B2 (en) * 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
CA2444590C (en) * 2001-04-18 2009-12-01 Robert L. Mcginnis Stabilized hemoglobin solutions
JP2005506832A (ja) 2001-05-14 2005-03-10 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー トランスメンブランセリンプロテアーゼ１０をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US7019117B2 (en) 2001-07-19 2006-03-28 Albert Einstein College Of Medicine Of Yeshiva University Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy alkylene glycols
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
PL368972A1 (en) 2001-08-29 2005-04-04 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
EP1487877B1 (en) 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
ES2654819T3 (es) 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
GB0127942D0 (en) * 2001-11-21 2002-01-16 Weston Medical Ltd Needleless injector drug capsule and a method for filing thereof
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
AU2002314790A1 (en) * 2001-12-05 2003-06-23 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
EE05509B1 (et) 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SI1485477T1 (sl) 2002-02-25 2009-10-31 Genentech Inc Novi citokinski receptor GLM-R tipa 1
US7001715B2 (en) * 2002-02-28 2006-02-21 Biopure Corporation Purification of red blood cells by separation and diafiltration
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
EP1501855A4 (en) * 2002-03-21 2006-02-22 Sagres Discovery Inc NEW COMPOSITIONS AND METHODS FOR CANCER
AU2003228809A1 (en) 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
MXPA04012243A (es) * 2002-06-07 2005-02-25 Genentech Inc Composiciones y metodos para l diagnostico y tratamiento de tumores.
DE10226990A1 (de) * 2002-06-18 2004-03-18 Sanguibiotech Ag Topisch applizierbare Mikro-Emulsionen mit binärer Phasen- und Wirkstoffdifferenzierbarkeit, deren Herstellung und deren Verwendung, insbesondere zur Versorgung der Haut mit bioverfügbarem Sauerstoff
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
EP2332956A1 (en) 2002-07-08 2011-06-15 Genentech, Inc. Antibody binding to PRO71238
WO2004012773A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
CN1692127A (zh) * 2002-07-25 2005-11-02 健泰科生物技术公司 Taci抗体及其用途
CN101792749B (zh) * 2002-08-12 2012-09-05 金克克国际有限公司 大肠杆菌AppA肌醇六磷酸酶突变体
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US7569214B2 (en) * 2002-09-09 2009-08-04 Nektar Therapeutics Al, Corporation Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
EP2116551A1 (en) 2002-09-11 2009-11-11 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004024097A2 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20050093759A (ko) 2002-09-18 2005-09-23 오르토-맥네일 파마슈티칼, 인코퍼레이티드 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
US20040072729A1 (en) * 2002-10-10 2004-04-15 Sunbio Inc. High oxygen affinity PEG-hemoglobin as treatment for brain stroke
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006516094A (ja) 2002-11-08 2006-06-22 ジェネンテック・インコーポレーテッド ナチュラルキラー細胞関連疾患の治療のための組成物と方法
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
JP2006508163A (ja) 2002-11-27 2006-03-09 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
US20040219214A1 (en) * 2002-12-30 2004-11-04 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
WO2004063963A2 (en) * 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1592708A2 (en) 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
CA2518371A1 (en) 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
RU2005141341A (ru) 2003-05-30 2006-06-10 Эйдженсис, Инк., Сша (Us) Полинуклеотид, родственный антигену стволовых клеток простаты (psca), и кодируемый им белок (пептид), гибридома и трансгенное животное для продуцирования антител, композиция для лечения, профилактики, диагностики и прогноза течения раковых заболеваний на их основе (варианты), способ определения их присутствия в исследуемом образце, способ генерации иммунного ответа, способ доставки цитотоксического или диагностического агента в клетку, способ ингибирования роста раковых клеток с их использованием
PL1631313T3 (pl) * 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
PL2784084T5 (pl) 2003-07-08 2024-12-02 Novartis Pharma Ag Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
KR101254371B1 (ko) 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
ES2341960T3 (es) 2003-07-22 2010-06-30 Nektar Therapeutics Procedimientos para preparar polimeros funcionalizados a partir de alcoholes polimericos.
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
ES2629696T3 (es) 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
EP1675620B1 (en) * 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
EP1675871A2 (en) 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2005035569A2 (en) * 2003-10-10 2005-04-21 Five Prime Therapeutics, Inc. Kiaa0779, splice variants thereof, and methods of their use
SI2295073T1 (sl) 2003-11-17 2014-07-31 Genentech, Inc. Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
EP2905033B1 (en) * 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
ES2720078T3 (es) * 2004-01-21 2019-07-17 Nektar Therapeutics Método para preparar polímeros terminados en ácido propiónico
US7135554B1 (en) 2004-01-27 2006-11-14 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
EP2327724A3 (en) * 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
WO2006078282A2 (en) 2004-04-28 2006-07-27 Angiotech Biomaterials Corporation Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
AU2005250370B2 (en) 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2006014729A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
EP1796602A4 (en) 2004-09-17 2016-10-19 Angiotech Pharm Inc MULTIFUNCTIONAL COMPOUNDS FOR PRODUCING NETWORKED BIOMATERIALS AND MANUFACTURING AND USE METHOD THEREFOR
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
ATE469174T1 (de) 2004-10-15 2010-06-15 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
AU2005322410B2 (en) 2004-11-30 2011-11-10 Amgen Fremont Inc. Antibodies directed to GPNMB and uses thereof
US20060134698A1 (en) * 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP1828224B1 (en) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
GB2438760A (en) * 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
CN102732588B (zh) * 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
WO2006133089A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
EP2412744B1 (en) 2005-07-18 2014-01-22 Nektar Therapeutics Method for preparing branched functionalised polymers using branched polyol cores
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
EP2277916A3 (en) * 2005-07-28 2011-04-27 Novartis AG Use of antibody to M-CSF
WO2007016285A2 (en) * 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
MX2008002149A (es) * 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
EP2360248A1 (en) 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
WO2007035583A1 (en) * 2005-09-19 2007-03-29 University Of Maryland, Baltimore Lyophilization of hemoglobin solutions
US8691944B2 (en) * 2005-10-04 2014-04-08 The Research Foundation For The State University Of New York Fibronectin polypeptides and methods of use
WO2007053524A2 (en) * 2005-10-28 2007-05-10 The Florida International University Board Of Trustees Horse: human chimeric antibodies
CN104710503B (zh) * 2005-11-08 2023-04-25 Ambrx 公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
EP1951890A4 (en) * 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
EP3023497A1 (en) 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
WO2007062090A2 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
DK1968635T3 (en) * 2005-12-14 2014-12-15 Ambrx Inc Compositions and Methods of, and uses of non-natural amino acids and polypeptides
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
JP2009524436A (ja) * 2006-01-24 2009-07-02 ノースフィールド ラボラトリーズ、インコーポレイテッド 重合したヘモグロビンの培地、並びに島細胞の単離及び移植におけるその使用
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
KR101513732B1 (ko) 2006-02-21 2015-04-21 넥타르 테라퓨틱스 분할된 분해가능한 폴리머 및 이로부터 제조된 컨주게이트
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
HRP20150884T1 (hr) 2006-03-21 2015-09-25 Genentech, Inc. Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2041174A2 (en) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
EP2057193B1 (en) 2006-08-04 2013-12-18 Novartis AG Ephb3-specific antibody and uses thereof
AR062435A1 (es) 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
US7795401B2 (en) 2006-09-06 2010-09-14 National Chung Cheng University Modified hemoglobin with allosteric effector conjugated
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
MX2009002460A (es) * 2006-09-08 2009-03-20 Ambrx Inc Arnt supresor hibrido para celulas de vertebrados.
EP2064333B1 (en) * 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP1914303A1 (en) * 2006-10-09 2008-04-23 Qiagen GmbH Thermus eggertssonii DNA polymerases
US7494974B2 (en) * 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
BRPI0718118A2 (pt) 2006-10-27 2017-05-30 Lpath Inc composições e métodos para ligação de sphingosine-1-fosfato
EP2083862A4 (en) 2006-10-27 2012-09-19 Lpath Inc COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
CA2668208C (en) 2006-11-02 2017-09-12 Daniel J. Capon Hybrid immunoglobulins with moving parts
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
KR20090087027A (ko) 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
KR101519672B1 (ko) 2006-12-07 2015-05-29 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
US7943728B2 (en) 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
US8507200B2 (en) * 2007-02-09 2013-08-13 Northwestern University Particles for detecting intracellular targets
US8088887B2 (en) * 2007-02-13 2012-01-03 Academia Sinica Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment
US8415453B2 (en) * 2007-02-13 2013-04-09 Academia Sinica Lung cancer-targeted peptides and applications thereof
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
US20090227981A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
US20090227689A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN101686939B (zh) * 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
MX2009011870A (es) * 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
EP2164992B1 (en) * 2007-05-30 2016-05-04 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
DK2160464T3 (da) * 2007-05-30 2014-08-04 Univ Northwestern Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CA2690734A1 (en) * 2007-06-14 2008-12-24 Richard A. Clark Polypeptides and methods of use
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
ES2559353T3 (es) 2007-07-26 2016-02-11 Amgen, Inc Enzimas lecitina-colesterol aciltransferasa modificadas
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
MX2010001363A (es) * 2007-08-09 2010-03-09 Syntonix Pharmaceuticals Inc Peptidos inmunomoduladores.
EP4248976B1 (en) 2007-08-23 2026-04-22 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CN111909273B (zh) * 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2214716B1 (en) 2007-10-23 2021-11-17 Nektar Therapeutics Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
MX2010005317A (es) * 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
ES2500066T3 (es) 2008-01-25 2014-09-30 Amgen, Inc Anticuerpos frente a ferroportina y métodos de uso
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
DK3153526T3 (da) 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8921315B1 (en) 2008-04-24 2014-12-30 Neumedicines, Inc. Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
WO2009140623A2 (en) 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
EP2296690B1 (en) 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
EP2318036B1 (en) * 2008-06-30 2015-06-03 The Regents of the University of Michigan Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
JP5611210B2 (ja) 2008-09-07 2014-10-22 グリコネックス インコーポレイテッド 抗拡張ｉ型スフィンゴ糖脂質抗体、その誘導体および使用
MX2011003272A (es) 2008-09-26 2011-04-28 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
NZ592420A (en) 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
US8481033B2 (en) 2008-10-07 2013-07-09 INSERM (Institute National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
WO2010048446A2 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
EA201190002A1 (ru) * 2008-11-06 2012-04-30 Гленмарк Фармасьютикалс С.А. Лечение антителами к интегрину альфа-2
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN106955360A (zh) 2008-11-24 2017-07-18 西北大学 多价rna纳米颗粒组合物
WO2010071894A2 (en) 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010081049A1 (en) * 2009-01-08 2010-07-15 Northwestern University Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
US20100294952A1 (en) * 2009-01-15 2010-11-25 Northwestern University Controlled agent release and sequestration
US20120064096A1 (en) 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
EP2408814B1 (en) 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MY173526A (en) 2009-03-25 2020-01-31 Genentech Inc Novel anti-?5?1 antibodies and uses thereof
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
TWI474833B (zh) 2009-04-01 2015-03-01 Genentech Inc 胰島素阻抗性疾病之治療
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
CN102458410A (zh) * 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
HRP20240135T1 (hr) * 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
KR102170375B1 (ko) * 2009-06-09 2020-10-27 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
US8324160B2 (en) * 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
US20110015130A1 (en) * 2009-07-20 2011-01-20 Woei-Jer Chuang Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof
EA201270184A1 (ru) 2009-07-21 2012-08-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Лечение расстройств печени ингибиторами pi3k
RU2567803C2 (ru) 2009-07-31 2015-11-10 Дженентек, Инк. ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
CA2778483A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Modulation of axon degeneration
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
DK2494075T3 (en) 2009-10-30 2018-07-23 Univ Northwestern TABLE-MANAGED NANOCONJUGATES
PH12012500901A1 (en) 2009-11-05 2016-08-05 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
WO2011066511A1 (en) 2009-11-30 2011-06-03 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof
BR112012012750A2 (pt) 2009-11-30 2020-08-11 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado e método
EP2679234A3 (en) * 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
US9044436B2 (en) 2009-12-23 2015-06-02 National Cheng Kung University Compositions and methods for the treatment of angiogenesis-related eye diseases
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
CA2789337A1 (en) 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
US8975376B2 (en) 2010-02-23 2015-03-10 Sanofi Anti-alpha2 integrin antibodies and their uses
TWI429453B (zh) 2010-02-23 2014-03-11 建南德克公司 抗tat419抗體及其用途
CA2791122C (en) 2010-02-25 2019-08-27 Sangart, Inc. Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
WO2011106723A2 (en) * 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
MX342239B (es) 2010-05-03 2016-09-21 Genentech Inc * Composiciones y metodos para el diagnostico y tratamiento de tumores.
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
US9878012B2 (en) 2010-05-18 2018-01-30 Neumedicines, Inc. IL-12 formulations for enhancing hematopoiesis
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
EP2582387A2 (en) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
WO2012010696A1 (en) 2010-07-23 2012-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
JP5462841B2 (ja) * 2010-08-16 2014-04-02 アークレイ株式会社 ヘモグロビンの分析方法
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
US8609815B2 (en) 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9445990B2 (en) 2010-10-06 2016-09-20 Medtronic, Inc. TNF inhibitor formulation for use in implantable infusion devices
WO2012061129A1 (en) 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
WO2012088265A1 (en) 2010-12-21 2012-06-28 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
SG192047A1 (en) 2011-01-24 2013-08-30 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012113813A1 (en) 2011-02-23 2012-08-30 F. Hoffmann-La Roche Ag Antibodies against human il33r and uses thereof
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
ES2612914T3 (es) 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
KR102001686B1 (ko) 2011-04-07 2019-07-18 암젠 인크 신규한 egfr 결합 단백질
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
HRP20190128T1 (hr) 2011-05-04 2019-03-08 Rhizen Pharmaceuticals S.A. Novi spojevi kao modulatori protein kinaza
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN103796666B (zh) 2011-05-18 2018-07-06 欧莫德里斯制药公司 改良的肽药物
KR20240110072A (ko) 2011-05-18 2024-07-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
KR102101806B1 (ko) 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
ES2682249T3 (es) 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
EP2718456B1 (en) 2011-06-13 2019-04-24 Neumedicines, Inc. Mitigation of cutaneous injury with il-12
EP2723761B1 (en) 2011-06-23 2017-11-08 The Regents of The University of Michigan Compound and method for modulating opioid receptor activity
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EP2744828A4 (en) 2011-08-16 2014-12-31 Univ Emory JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
CA2842481A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
US9889209B2 (en) 2011-09-14 2018-02-13 Northwestern University Nanoconjugates able to cross the blood-brain barrier
SG11201400859SA (en) 2011-09-22 2014-04-28 Amgen Inc Cd27l antigen binding proteins
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013055809A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
EP3501536B1 (en) 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
EP2773659A2 (en) 2011-10-31 2014-09-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
JP2015501639A (ja) 2011-11-23 2015-01-19 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗ｃｄ９８抗体およびその使用方法
CN108653715A (zh) 2011-12-16 2018-10-16 卡乐斯治疗公司 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
CA2862290A1 (en) 2012-01-18 2013-10-17 Neumedicines, Inc. Il-12 for radiation protection and radiation-induced toxicity mitigation
CA2861392C (en) 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
SI2834241T1 (sl) 2012-03-05 2021-06-30 Gilead Calistoga Llc Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA
JP6200437B2 (ja) 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2908236C (en) * 2012-03-29 2021-10-26 Schindler, William Diaspirin crosslinked pegylated hemoglobin
CN104411332B (zh) 2012-03-30 2018-11-23 索伦托治疗有限公司 与vegfr2结合的全人抗体
EP2831073B1 (en) 2012-03-30 2020-12-09 Rhizen Pharmaceuticals S.A. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013169734A1 (en) 2012-05-07 2013-11-14 Amgen Inc. Anti-erythropoietin antibodies
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
PL2859017T3 (pl) 2012-06-08 2019-07-31 Sutro Biopharma, Inc. Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
WO2013192594A2 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
DK3431497T3 (da) 2012-06-27 2022-10-10 Univ Princeton Spaltede inteiner, konjugater og anvendelser deraf
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
ES3047691T3 (en) 2012-08-01 2025-12-04 Ikaika Therapeutics Inc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
HRP20220455T1 (hr) 2012-08-31 2022-05-27 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azid grupu
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
WO2014040076A1 (en) 2012-09-10 2014-03-13 Xencor Methods of treating neurological diseases
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
CN104918961A (zh) 2012-11-20 2015-09-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
DK2922877T3 (da) 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
HUE033369T2 (en) 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
ES2871816T3 (es) 2012-12-27 2021-11-02 Sanofi Sa Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
EP2951206A2 (en) 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2014140358A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
CN105188761B (zh) * 2013-03-15 2020-05-15 桑加特公司 聚环氧烷戊酸酯血红蛋白缀合物
US11220556B2 (en) 2013-03-15 2022-01-11 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA2902739C (en) 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP3001813B1 (en) * 2013-05-13 2019-03-27 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
SI3456743T1 (sl) 2013-05-30 2022-01-31 Kiniksa Pharmaceuticals, Ltd. Proteini, ki vežejo antigen receptorja onkostatina M
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
JP6267792B2 (ja) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JP6419796B2 (ja) 2013-10-04 2018-11-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３に特異的に結合する抗体
SI3055331T1 (sl) 2013-10-11 2021-04-30 Oxford Bio Therapeutics Limited Konjugirana protitelesa proti LY75 za zdravljenje raka
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
WO2015066027A2 (en) 2013-10-28 2015-05-07 Dots Devices, Inc. Allergen detection
PL3063275T3 (pl) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Terapeutyczne fuzje nukleaza-albumina i sposoby
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
WO2015095601A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
EP3094646B1 (en) 2014-01-13 2020-04-15 Valerion Therapeutics, LLC Internalizing moieties
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
WO2016039801A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
RU2019119862A (ru) 2014-02-20 2019-07-15 Аллерган, Инк. Антитела к компоненту комплемента c5
AU2015223056B2 (en) 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
EP3113798B1 (en) 2014-03-07 2019-06-05 University Health Network Methods and compositions for modifying the immune response
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
EP3131929B1 (en) 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
CN117180445A (zh) 2014-05-28 2023-12-08 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
KR102366644B1 (ko) 2014-05-30 2022-02-22 상하이 헨리우스 바이오테크, 인크. 항-표피 성장 인자 수용체 (egfr) 항체
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
AU2015295242B2 (en) 2014-07-31 2020-10-22 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
EP3186276B1 (en) 2014-08-27 2019-07-10 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
DK3209778T3 (da) 2014-10-24 2019-05-27 Astrazeneca Kombination
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
IL313511A (en) 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
CN111018987B (zh) 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
CA2968352A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
EP3916017A1 (en) 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
CN105802948B (zh) 2014-12-29 2020-06-09 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用
DK3240801T3 (da) 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
CR20170383A (es) 2015-01-23 2017-11-22 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
US10266584B2 (en) 2015-02-09 2019-04-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
CN108271359B (zh) 2015-02-13 2021-11-09 索伦托药业有限公司 结合ctla4的抗体治疗剂
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
ES2927119T3 (es) 2015-04-08 2022-11-02 Sorrento Therapeutics Inc Productos terapéuticos de anticuerpos que se unen a CD38
MY188430A (en) 2015-04-10 2021-12-08 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
ES2945313T3 (es) 2015-04-17 2023-06-30 Amgen Res Munich Gmbh Construcciones de anticuerpos biespecificos para CDH3 y CD3
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US10519207B2 (en) 2015-06-12 2019-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for treating opioid tolerance
US10266589B2 (en) 2015-07-29 2019-04-23 Allergan, Inc. Heavy chain only antibodies to ANG-2
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
WO2017030909A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
DK3344655T5 (da) 2015-09-01 2024-10-07 Boehringer Ingelheim Int Brug af anti-cd40-antistoffer til behandling af lupus nefritis
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
WO2017059371A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
WO2017062966A1 (en) 2015-10-09 2017-04-13 Florida State University Research Foundation, Inc. Antibodies specific for 4,6-diamino-5-(formyulamino) pyrimidine and uses thereof
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
AU2016365423A1 (en) 2015-12-04 2018-07-12 The Regents Of The University Of California Novel antibodies for the treatment of cancers
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
EA037855B1 (ru) 2016-01-29 2021-05-27 Сорренто Терапьютикс, Инк. Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1
CN116063544A (zh) 2016-02-03 2023-05-05 安进研发（慕尼黑）股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
EP3411404B1 (en) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma and cd3 bispecific t cell engaging antibody constructs
JP7157981B2 (ja) 2016-03-07 2022-10-21 チャールストンファーマ， エルエルシー 抗ヌクレオリン抗体
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
JP6925579B2 (ja) * 2016-03-31 2021-08-25 日油株式会社 環状ベンジリデンアセタール構造を有する生分解性ヒドロゲル
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
KR102687530B1 (ko) 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP4316595A3 (en) 2016-09-02 2024-04-17 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
EP3509616A1 (en) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
WO2018052818A1 (en) 2016-09-16 2018-03-22 Henlix, Inc. Anti-pd-1 antibodies
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
US10941195B2 (en) 2016-10-04 2021-03-09 Fairbanks Pharmaceuticals, Inc. Anti-follistatin-like 3 antibodies and treatment of diabetes
CN110214147A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
AU2017343752B2 (en) 2016-10-14 2021-12-16 Neomatrix Therapeutics, Inc Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
BR112019008010A2 (pt) 2016-10-20 2019-07-09 I-Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
JP7136468B2 (ja) 2016-11-08 2022-09-13 ユニバーシティ オブ マイアミ 抗セクレトグラニンｉｉｉ（ｓｃｇ３）抗体およびその使用
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
MX2019008529A (es) 2017-01-19 2020-02-07 Us Health Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).
TN2019000225A1 (en) 2017-02-02 2021-01-07 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
US10729741B2 (en) 2017-03-27 2020-08-04 Neomatrix Therapeutics Inc. Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
MX2019013142A (es) 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
AU2018281337B2 (en) 2017-06-06 2022-08-25 Relinia, Inc. Single-chain TNF receptor 2 agonist fusion proteins
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
IL271504B2 (en) 2017-06-21 2024-05-01 Jazz Pharmaceuticals Ireland Ltd Modified l-asparaginase
EP3418383A1 (en) 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
CA3069295A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
US20190091298A1 (en) 2017-07-07 2019-03-28 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
AU2018361819B2 (en) 2017-11-02 2025-01-09 Oxford Biotherapeutics Ltd Antibodies and methods of use
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018369639C1 (en) 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
KR20250111232A (ko) 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
JP7490565B2 (ja) 2017-12-29 2024-05-27 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
BR112020013644A2 (pt) 2018-01-03 2020-12-01 Mederis Diabetes, Llc produto de peptídeo ou sal farmaceuticamente aceitável do mesmo para uso no tratamento de síndrome de ovário policístico, um distúrbio renal ou um distúrbio hepático, e, kit.
BR112020015016A2 (pt) 2018-01-26 2020-12-29 Genentech, Inc. Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
AU2019212709A1 (en) 2018-01-26 2020-08-13 Genentech, Inc. IL-22 Fc fusion proteins and methods of use
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
WO2019160976A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
JP2021514354A (ja) 2018-02-21 2021-06-10 ジェネンテック， インコーポレイテッド ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
US20210032334A1 (en) 2018-02-28 2021-02-04 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
US11485782B2 (en) 2018-03-14 2022-11-01 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN117003874A (zh) 2018-03-20 2023-11-07 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CA3094644A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
KR20210007959A (ko) 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도
EP3774916A2 (en) 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
KR102890791B1 (ko) 2018-04-09 2025-11-24 체크메이트 파마슈티칼스, 인크. 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US11065336B2 (en) 2018-04-30 2021-07-20 Medimmune Limited Conjugates for targeting and clearing aggregates
CA3098416A1 (en) 2018-04-30 2019-11-07 Takeda Pharmaceutical Company Limited Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
EP3802602A1 (en) 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN119613548A (zh) 2018-06-13 2025-03-14 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
MX2020012107A (es) 2018-06-18 2021-01-29 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
EP3806889A4 (en) 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
JP7637415B2 (ja) 2018-06-22 2025-02-28 キュージーン インコーポレイテッド インターロイキン－２バリアントおよびその使用方法
WO2020006347A1 (en) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
CN112384532B (zh) 2018-06-29 2025-01-10 艾利妥 抗SIRP-β1抗体及其使用方法
TW202519260A (zh) 2018-07-02 2025-05-16 美商安進公司 抗steap1抗原結合蛋白
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
WO2020025532A1 (en) 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
JOP20210022A1 (ar) 2018-08-03 2021-01-28 Amgen Inc بنيات جسم مضاد لـ cldn18.2وcd3
WO2020047326A2 (en) 2018-08-31 2020-03-05 ALX Oncology Inc. Decoy polypeptides
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
EP3856343A1 (en) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
EP3856773A1 (en) 2018-09-28 2021-08-04 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them
US20220089786A1 (en) 2019-01-04 2022-03-24 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
US12128090B2 (en) 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
WO2020161214A1 (en) 2019-02-07 2020-08-13 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
TW202540426A (zh) 2019-02-27 2025-10-16 美商Ionis製藥公司 Malat1表現之調節劑
UA128825C2 (uk) 2019-03-01 2024-10-30 Ксенкор, Інк. Гетеродимерні антитіла, що зв'язують enpp3 та cd3
CN113614477B (zh) 2019-03-14 2023-04-28 泰尔茂比司特生物技术有限公司 冷冻干燥装载托盘组件及系统
WO2020191365A1 (en) 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
KR20220004979A (ko) 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
EP3952999A4 (en) 2019-04-09 2023-01-25 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2020223121A1 (en) 2019-04-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US12590386B2 (en) 2019-04-30 2026-03-31 Gigagen, Inc. Recombinant polyclonal proteins and methods of use thereof
MX2021013671A (es) 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.
CN113966224A (zh) 2019-06-04 2022-01-21 Ra制药公司 采用补体抑制剂的炎性疾病治疗
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN114008077B (zh) 2019-07-03 2024-10-29 牛津生物疗法有限公司 抗体和使用方法
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
MX2022001260A (es) 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
US20220281967A1 (en) 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
AU2020328038B2 (en) 2019-08-13 2025-10-09 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
US20220401524A1 (en) 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
US11987612B2 (en) 2019-11-04 2024-05-21 Alector Llc Siglec-9 ECD fusion molecules
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
BR112022010425A2 (pt) 2019-12-03 2022-08-23 Evotec Int Gmbh Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
KR20220109436A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 인터페론-결합된 항원 결합 단백질 및 이의 용도
WO2021113596A2 (en) 2019-12-05 2021-06-10 Sorrento Therapeutics, Inc. Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody
JP2023506465A (ja) 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法
MX2022007712A (es) 2019-12-17 2022-09-26 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
WO2021119827A1 (en) 2019-12-19 2021-06-24 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
JP2023525423A (ja) 2020-01-15 2023-06-16 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
CN115427447B (zh) 2020-01-17 2025-02-18 百进生物科技公司 抗tlr7药剂和组合物以及制备和使用其的方法
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
US20230075965A1 (en) 2020-01-24 2023-03-09 Constantine S. Mitsiades Uses of biomarkers for improving immunotherapy
KR20220150303A (ko) 2020-02-04 2022-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의한 중증 폰 빌레브란트병 환자의 월경과다 치료
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
CN115485300A (zh) 2020-02-26 2022-12-16 索伦托药业有限公司 具有通用掩蔽部分的可活化的抗原结合蛋白
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
JP2023519962A (ja) 2020-03-31 2023-05-15 アレクトル エルエルシー 抗ｍｅｒｔｋ抗体及びその使用方法
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
MX2022012752A (es) 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
AU2021281554A1 (en) 2020-05-29 2022-12-15 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3
CA3177152A1 (en) 2020-06-12 2021-12-16 David Scott Johnson Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
US12497463B2 (en) 2020-06-23 2025-12-16 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-CD38 antibody and use thereof
WO2021263166A1 (en) 2020-06-26 2021-12-30 Sorrento Therapeutics, Inc. Anti-pd1 antibodies and uses thereof
EP4171614A1 (en) 2020-06-29 2023-05-03 Resolve Therapeutics, LLC Treatment of sjogren's syndrome with nuclease fusion proteins
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
EP4188960A4 (en) 2020-08-03 2024-09-11 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION IN VIROTHERAPEUTIC PRODUCTS
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
KR20230062600A (ko) 2020-09-04 2023-05-09 메르크 파텐트 게엠베하 항-ceacam5 항체 및 접합체 및 이의 용도
JP2023542678A (ja) 2020-09-21 2023-10-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症状態の処置のための抗ｃｄ４０抗体の使用。
US20220127344A1 (en) 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
EP4240767A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Polypeptide constructs binding to cd3
CN116323671A (zh) 2020-11-06 2023-06-23 安进公司 具有增加的选择性的多靶向性双特异性抗原结合分子
IL301926A (en) 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced clipping rate
US12564642B2 (en) 2020-11-10 2026-03-03 Sanofi CEACAM5 antibody-drug conjugate formulation
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
EP4263599A1 (en) 2020-12-16 2023-10-25 Voyager Therapeutics, Inc. Tau binding compounds
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
JP2024504696A (ja) 2021-01-20 2024-02-01 バイオアントレ エルエルシー Ｃｔｌａ４結合性タンパク質およびがんを処置する方法
EP4284828A1 (en) 2021-01-28 2023-12-06 Talem Therapeutics LLC Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
US20240317868A1 (en) 2021-02-05 2024-09-26 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024512002A (ja) 2021-03-18 2024-03-18 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
AU2022246164A1 (en) 2021-03-26 2023-09-28 The Brigham And Women’S Hospital, Inc. Anti-klrg1 antibodies
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
CN115141276A (zh) 2021-03-31 2022-10-04 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
MX2023011690A (es) 2021-04-02 2023-12-15 Amgen Inc Construcciones de unión a mageb2.
US20250161471A1 (en) 2021-04-03 2025-05-22 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
CN117279947A (zh) 2021-05-06 2023-12-22 安进研发（慕尼黑）股份有限公司 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
BR112023025194A2 (pt) 2021-06-04 2024-02-27 Boehringer Ingelheim Int Anticorpos anti-sirp-alfa
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022258720A1 (en) 2021-06-09 2022-12-15 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
US20240279341A1 (en) 2021-06-16 2024-08-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗ＭｅｒＴＫ抗体及びその使用方法
MX2024001277A (es) 2021-07-26 2024-02-15 Abcuro Inc Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1).
EP4419558A1 (en) 2021-10-19 2024-08-28 Alector LLC Anti-cd300lb antibodies and methods of use thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023099682A1 (en) 2021-12-02 2023-06-08 Sanofi Ceacam5 adc–anti-pd1/pd-l1 combination therapy
KR20240112348A (ko) 2021-12-02 2024-07-18 사노피 암 치료법에서 환자 선택을 위한 cea 검정
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
IL315397A (en) 2022-03-09 2024-11-01 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
AR128745A1 (es) 2022-03-09 2024-06-12 Merck Patent Gmbh Anticuerpos y conjugados anti-ceacam5 y usos de los mismos
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
US20260053913A1 (en) 2022-06-10 2026-02-26 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
CA3262035A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
CN119301155A (zh) 2022-07-19 2025-01-10 百进生物科技公司 抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法
TW202415679A (zh) 2022-07-29 2024-04-16 美商阿列克特有限責任公司 抗ｇｐｎｍｂ抗體及其使用方法
CN119968395A (zh) 2022-08-18 2025-05-09 百进生物科技公司 抗axl抗体、其抗原结合片段及其制备和使用方法
JP2025531814A (ja) 2022-09-08 2025-09-25 ジーマックス バイオファーム エルエルシー Ｇｉｐｒ抗体、ｆｇｆ２１との融合タンパク質、その医薬組成物及びその使用
US20260083841A1 (en) 2022-09-14 2026-03-26 Amgen Inc. Bispecific Molecule Stabilizing Composition
US20260092121A1 (en) 2022-10-14 2026-04-02 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
EP4615480A1 (en) 2022-11-07 2025-09-17 Alector LLC Uses of siglec-9 ecd fusion molecules in cancer treatment
TW202435917A (zh) 2022-11-17 2024-09-16 美商西雅圖遺傳學公司 Ceacam5抗體-藥物接合物及其使用方法
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
EP4646270A2 (en) 2023-01-06 2025-11-12 Alector LLC Anti-il18 binding protein antibodies and methods of use thereof
CN121127494A (zh) 2023-01-06 2025-12-12 武田药品工业株式会社 用于治疗自身免疫性疾病的抗cd38抗体
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
WO2024243217A1 (en) 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof
US20250011368A1 (en) 2023-06-14 2025-01-09 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
CN121712787A (zh) 2023-06-14 2026-03-20 马里亚纳肿瘤学公司 靶向dll3的肽及其构建体
US20250049970A1 (en) 2023-06-14 2025-02-13 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
MX2025014635A (es) 2023-06-14 2026-02-03 Amgen Inc Moleculas captadoras de enmascaramiento de celulas t
TW202506719A (zh) 2023-07-27 2025-02-16 德商艾瑪提克生物技術有限公司 針對mageb2之抗原結合蛋白
AU2024323812A1 (en) 2023-08-15 2026-03-12 Gigagen, Inc. Recombinant polyclonal proteins targeting hepatitis b virus (hbv) and methods of use thereof
WO2025037108A2 (en) 2023-08-15 2025-02-20 Board Of Trustees Of The Leland Stanford Junior University Modified thrombopoietin
CN121816366A (zh) 2023-09-27 2026-04-07 百进公司 抗gpc4抗体
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules
TW202535461A (zh) 2023-10-06 2025-09-16 德商百靈佳殷格翰國際股份有限公司 使用抗ｓｉｒｐａ抗體治療肝臟疾病或病症
TW202535460A (zh) 2023-10-06 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗ＳＩＲＰ－α抗體用於治療癌症之用途
US20250186541A1 (en) 2023-11-27 2025-06-12 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
WO2025122615A1 (en) 2023-12-05 2025-06-12 Mariana Oncology Inc. Enriched and stable radioligand therapy formulations and pharmaceutical compositions comprising same
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025155843A1 (en) 2024-01-19 2025-07-24 Akero Therapeutics, Inc. Method of treating liver or lung injury
TW202600175A (zh) 2024-02-15 2026-01-01 德商馬克專利公司 用於治療gd2陽性癌症之抗gd2抗體及免疫結合物
TW202602919A (zh) 2024-03-01 2026-01-16 德商百靈佳殷格翰國際股份有限公司 結締組織生長因子(ctgf)之抗體及其用途
WO2025193746A1 (en) 2024-03-12 2025-09-18 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia
TW202602929A (zh) 2024-03-21 2026-01-16 美商思進公司 Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途
WO2025210264A1 (en) 2024-04-04 2025-10-09 Merck Patent Gmbh Antibody-drug-conjugates binding napi2b
WO2025235919A1 (en) 2024-05-09 2025-11-13 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2025254987A1 (en) 2024-06-03 2025-12-11 Alector Llc Siglec-9 ecd fusion molecule variants and methods of use thereof
WO2026024904A1 (en) 2024-07-24 2026-01-29 Gigagen, Inc. Custom recombinant polyclonal proteins and methods of use thereof
WO2026033259A1 (en) 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026072990A1 (en) 2024-09-27 2026-04-02 Abcuro, Inc. Methods of treating t-cell large granular lymphocytic leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941710A (en) * 1972-04-24 1976-03-02 Lever Brothers Company Phosphate - free dishwashing compositions containing an alkyl polyether carboxylate surfactant
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
JPS5989629A (ja) * 1982-11-15 1984-05-23 Ajinomoto Co Inc 代用血液
JPS59104323A (ja) * 1982-12-07 1984-06-16 Ajinomoto Co Inc 代用血液
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
FR2551660B1 (fr) * 1983-09-13 1986-11-14 Centre Nat Rech Scient Hemoglobine modifiee chimiquement, sa preparation, solutions aqueuses en contenant et leur utilisation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667292B1 (en) 1999-02-08 2003-12-23 Hokkaido University Nitric monoxide metabolite-polyoxyalkylene-hemoglobin complex

Also Published As

Publication number Publication date
JPS6289630A (ja) 1987-04-24
EP0206448A1 (en) 1986-12-30
EP0206448B1 (en) 1990-11-14
DE3675588D1 (de) 1990-12-20
US4670417A (en) 1987-06-02

Similar Documents

Publication Publication Date Title
JPH0676333B2 (ja) ヘモグロビン―ポリオキシアルキレン結合体
US6962972B2 (en) Derivatization of proteins
US4301144A (en) Blood substitute containing modified hemoglobin
US5334382A (en) Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions
US4377512A (en) Oxygen carrier for blood substitute
US5066590A (en) Superoxide dismutase combined with a poly(alkylene oxide)
JPH026337B2 (ja)
JPH06506217A (ja) ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
EP0377613B1 (en) Conjugates of superoxide dismutase
US20040023851A1 (en) Method for the porduction of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross- linking in the presence of chemically non- reacting effectors of the oxygen affinity of the haemoglobin
US6956025B2 (en) Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
CA1266550A (en) Polymer resins with amino acid containing pendants for sorption of bile pigments and bile acids
EP1725583A2 (en) Methods for increasing protein polyethylene glycol (peg) conjugation
JP2531661B2 (ja) 酸素運搬剤
EP0632082B1 (en) Preparation of activated carbamates of poly(alkylene glycol) and their use
JP2501543B2 (ja) ヘモグロビン−ポリオキシアルキレン結合体凍結乾燥製剤
Xue et al. [20] Preparation of conjugated hemoglobins
US6326178B1 (en) Method for synthesizing a composite of a conductive macromolecule and a protein
JPS59104323A (ja) 代用血液
JPH0564128B2 (ja)
KR100291828B1 (ko) 폴리에틸렌글리콜-석시니미딜프로피오네이트
JPS5989629A (ja) 代用血液
CN101002943A (zh) 支链peg－gcsf和peg－gmcsf结合物及其制备方法
JPH04262781A (ja) ゼラチンで修飾されたスーパーオキシドジスムターゼ
MXPA98000883A (en) Compositions of therapeutic agent stabilized by conjugation, supply and formulations of diagnost

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term